BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19447172)

  • 41. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
    Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; DonĂ  G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
    Saha B; Parks RJ
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
    McGee-Lawrence ME; McCleary-Wheeler AL; Secreto FJ; Razidlo DF; Zhang M; Stensgard BA; Li X; Stein GS; Lian JB; Westendorf JJ
    Bone; 2011 May; 48(5):1117-26. PubMed ID: 21255693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
    Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
    Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.
    Singh RK; Lall N; Leedahl TS; McGillivray A; Mandal T; Haldar M; Mallik S; Cook G; Srivastava DK
    Biochemistry; 2013 Nov; 52(45):8139-49. PubMed ID: 24079912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
    Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
    Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors.
    Kenny RG; Ude Z; Docherty JR; Marmion CJ
    J Inorg Biochem; 2020 May; 206():110981. PubMed ID: 32088592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model.
    Matsushita Y; Araki K; Omotuyi Oi; Mukae T; Ueda H
    Br J Pharmacol; 2013 Nov; 170(5):991-8. PubMed ID: 24032674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors.
    Andrews KT; Gupta AP; Tran TN; Fairlie DP; Gobert GN; Bozdech Z
    PLoS One; 2012; 7(2):e31847. PubMed ID: 22384084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
    Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
    Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.
    Zhou X; Yang XY; Popescu NC
    Biochem Biophys Res Commun; 2012 Apr; 420(2):325-30. PubMed ID: 22425986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
    Deroanne CF; Bonjean K; Servotte S; Devy L; Colige A; Clausse N; Blacher S; Verdin E; Foidart JM; Nusgens BV; Castronovo V
    Oncogene; 2002 Jan; 21(3):427-36. PubMed ID: 11821955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity.
    Ieda N; Yamada S; Kawaguchi M; Miyata N; Nakagawa H
    Bioorg Med Chem; 2016 Jun; 24(12):2789-93. PubMed ID: 27143132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.